Vita Life SciencesASX:VLS 94 Days Payable is 88.36 as of Dec. 2025, which is 45% above its 10-year median of 60.76. GuruFocus rates ASX:VLS with a GF Score™ of 94/100 and a GF Value™ of A$2.47 (Fairly Valued). The stock has 1 warning sign investors should review. Among 923 Drug Manufacturers companies, Vita Life Sciences ranks worse than 58.07% on this metric.
The historical rank and industry rank for Vita Life Sciences's Days Payable or its related term are showing as below:
ASX:VLS'
s Days Payable Range Over the Past 10 Years
Min: 55.89 Med: 60.76 Max: 77.51
Current: 77.51
During the past 13 years, Vita Life Sciences's highest Days Payable was 77.51. The lowest was 55.89. And the median was 60.76.
ASX:VLS's Days Payable is ranked worse than 58.07% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs ASX:VLS: 77.51
Vita Life Sciences's Days Payable
declined
from Dec. 2024 (104.52) to Dec. 2025 (88.36).
It may suggest that Vita Life Sciencesaccelerated paying its suppliers.
Vita Life Sciences Days Payable Related Terms
Vita Life Sciences Days Payable Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Vita Life Sciences's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vita Life Sciences (ASX:VLS) has a Days Payable of 88.36 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vita Life Sciences and its competitors. This is 45% above median its historical median of 60.76. Over the past decade, Vita Life Sciences' Days Payable has ranged from 55.89 to 77.51. According to the industry distribution chart, Vita Life Sciences ranks #536 out of 923 companies in the Drug Manufacturers industry, placing it in the top 58.1%.
Is Vita Life Sciences' Days Payable too high?
Vita Life Sciences' current Days Payable of 88.36 is 45% above median its 10-year median of 60.76. Over the past 10 years, this metric has ranged from a low of 55.89 to a high of 77.51. The Drug Manufacturers industry median Days Payable is 90.98. Vita Life Sciences' value of 88.36 is 2.9% below this industry median. Based on the distribution chart, Vita Life Sciences ranks #536 out of 923 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Vita Life Sciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #536 out of 923 companies for Days Payable. This places Vita Life Sciences in the lower half of its industry. The industry median Days Payable is 90.98. Vita Life Sciences' value of 88.36 is 2.9% below this benchmark. Historically, Vita Life Sciences' own Days Payable has ranged from 55.89 to 77.51 over the past decade. While the company's 10-year median is 60.76 vs. the industry median of 90.98, Vita Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current Days Payable of 88.36 is 2.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current Days Payable is 88.36, which is 45% above median its own 10-year median of 60.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.47, compared to a current price of A$2.50 — trading 1.2% above its estimated fair value. The current Days Payable is 88.36, which is 45% above median its 10-year median of 60.76 and 2.9% below the Drug Manufacturers industry median of 90.98. Vita Life Sciences' overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current Days Payable is 88.36 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be overvalued.
The current stock price of A$2.50 is trading 1.2% above its estimated GF Value™ of A$2.47.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
Days Payable: 88.36 (45% above median its 10-year median of 60.76)
GF Value™: A$2.47 vs. price of A$2.50 (1.2% above fair value)
Industry Position: 2.9% below the Drug Manufacturers median (#536 of 923)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
94GF Score
Get the complete analysis for ASX:VLS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
